Related Experiment Video
Updated: Nov 20, 2025
Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
Published on: February 23, 2024
The iron chelator deferoxamine decreases myeloma cell survival
Feifei Yang1, Zhaoxian Wu1, Dan Dai1
1Department of Hematology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Objective:
This study evaluated serum ferritin (SF) levels and investigated their relationships with various clinical markers in patients with multiple myeloma (MM). Furthermore, the effects and molecular mechanism of deferoxamine (DFO) in myeloma cells were studied.
Methods:
Clinical data from 84 patients with MM were collected to evaluate SF content and its relationship with several important clinical parameters. MM1S and MM1R myeloma cells were chosen to investigate the effects of iron and DFO on cell survival and apoptosis.
Results:
Increased SF levels were detected in newly diagnosed patients, especially those with stage III disease or the κ isotype. SF content was positively correlated with β2-microglobulin, interleukin-6, and lactate dehydrogenase expression. Furthermore, patients with progressive or relapsed disease had higher SF levels. Importantly, iron chelation with DFO efficiently inhibited myeloma cell survival and accelerated apoptosis by regulating apoptosis-related genes.
Conclusions:
The importance of SF for MM was highlighted. Additionally, it is suggested that DFO may be a good therapeutic option for MM.
